Surgery pp 2061-2085 | Cite as

Soft Tissue Sarcoma

  • Peter W. T. Pisters


Soft tissue sarcomas comprise a group of relatively rare, anatomically and histologically diverse neoplasms. These tumors share a common embryological origin, arising primarily from tissues derived from the mesoderm. The notable exceptions are neurosarcomas, primitive neuroectodermal tumors, and possibly E wing’s sarcomas, which are believed to arise from tissues of ectodermal origin.


Soft Tissue Sarcoma Malignant Peripheral Nerve Sheath Tumor Soft Tissue Sarcoma Pulmonary Metastasectomy Retroperitoneal Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA J Clin 1999;49:8–31.CrossRefGoogle Scholar
  2. 2.
    Lawrence W Jr, Donegan WL, Natarajan N, et al. Adult soft tissue sarcomas, a pattern of care survey of the American College of Surgeons. Ann Surg 1987;205:349–359.PubMedCrossRefGoogle Scholar
  3. 3.
    Feigen M. Should cancer survivors fear radiation-induced sarcomas? Sarcoma 1997;1:5–15.PubMedCrossRefGoogle Scholar
  4. 4.
    Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch Surg 1992;127:1379–1385.PubMedGoogle Scholar
  5. 5.
    Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl J Med 1986;314:1010–1015.PubMedGoogle Scholar
  6. 6.
    Zoller MET, Rembeck B, Oden A, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer (Phila) 1997;79:2125–2131.PubMedCrossRefGoogle Scholar
  7. 7.
    Jones IT, Jagelman DG, Fazio VW, et al. Desmoid tumors in familial polyposis coli. Ann Surg 1986;204:94–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Weiss SW, Sobin LH. Histologic Typing of Soft Tissue Tumors, 2nd ed. Berlin: Springer-Verlag, 1994.Google Scholar
  9. 9.
    Presant CA, Russell WO, Alexander RW, et al. Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions: the Southeastern Cancer Study Group experience. J Clin Oncol 1986;4:1658–1661.PubMedGoogle Scholar
  10. 10.
    Shiraki M, Enterline HT, Brooks JJ, et al. Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer (Phila) 1989;64:484–490.PubMedCrossRefGoogle Scholar
  11. 11.
    Fong Y, Coit DG, Woodruff JM, et al. Lymph node metastasis from soft tissue sarcoma in adults: analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993;217:72–77.PubMedCrossRefGoogle Scholar
  12. 12.
    Weingrad DN, Rosenberg SA. Early lymphatic spread of osteogenic and soft-tissue sarcomas. Surgery (St. Louis) 978;84:231–240.Google Scholar
  13. 13.
    Pisters PWT, Leung DHY, Woodruff J, et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679–1689.PubMedGoogle Scholar
  14. 14.
    Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996;14:869–877.PubMedGoogle Scholar
  15. 15.
    Costa J, Wesley RA, Glatstein E, et al. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer (Phila) 1984;53:530–541.PubMedCrossRefGoogle Scholar
  16. 16.
    Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults: study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33:37–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350–362.PubMedGoogle Scholar
  18. 18.
    Chang AE, Matory YL, Dwyer AJ, et al. Magnetic resonance imaging versus computed tomography in the evaluation of soft tissue tumors of the extremities. Ann Surg 1987;205:340–348.PubMedCrossRefGoogle Scholar
  19. 19.
    Hanna SL, Fletcher BD. MR imaging of malignant soft-tissue tumors. Magn Reson Imaging Clin N Am 1995;3:629–650.PubMedGoogle Scholar
  20. 20.
    Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology 1997;202:237–246.PubMedGoogle Scholar
  21. 21.
    Fleming JB, Holtz D, Cantor SB, et al. The utility and cost-effectiveness of computerized tomography (CT) to screen for pulmonary metastases in patients presenting with T1 extremity soft tissue sarcomas (STS) [abstract]. Proc Am Soc Clin Oncol 1998;17:1989.Google Scholar
  22. 22.
    Heslin MJ, Lewis JJ, Woodruff JM, et al. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 1997;4:425–431.PubMedCrossRefGoogle Scholar
  23. 23.
    Ball AB, Fisher C, Pittam M, et al. Diagnosis of soft tissue tumours by Tru-Cut biopsy. Br J Surg 1990;77:756–758.PubMedCrossRefGoogle Scholar
  24. 24.
    Skrzynski MC, Biermann JS, Montag A, et al. Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. J Bone Joint Surg [Am] 1996;78:644–649.PubMedGoogle Scholar
  25. 25.
    Schwartz HS, Spengler DM. Needle tract recurrences after closed biopsy for sarcoma: three cases and review of the literature. Arm Surg Oncol 1997;4:228–236.CrossRefGoogle Scholar
  26. 26.
    Akerman M. Fine-needle aspiration cytology of soft tissue sarcoma: benefits and limitations. Sarcoma 1998;2:155–161.PubMedCrossRefGoogle Scholar
  27. 27.
    Akerman M, Idvall I, Rydholm A. Cytodiagnosis of soft tissue tumors and tumor-like conditions by means of fine needle aspiration biopsy. Arch Orthop Trauma Surg 1980;96:61–67.PubMedCrossRefGoogle Scholar
  28. 28.
    Kissin MW, Fisher C, Webb AJ, et al. Value of fine needle aspiration cytology in the diagnosis of soft tissue tumours: a preliminary study on the excised specimen. Br J Surg 1987;74:479–480.PubMedCrossRefGoogle Scholar
  29. 29.
    Layfield LJ, Anders, KH, Glasgow BJ, et al. Fine-needle aspiration of primary soft-tissue lesions. Arch Pathol Lab Med 1986;110:420–424.PubMedGoogle Scholar
  30. 30.
    Soft tissue sarcoma. In: Fleming ID, Cooper JS, Henson DE, et al., eds. American Joint Committee on Cancer (AJCC) Staging Manual, 5th ed. Philadelphia: Lippincott-Raven, 1997:149–156.Google Scholar
  31. 31.
    Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992;10:1317–1329.PubMedGoogle Scholar
  32. 32.
    Markhede G, Angervall L, Stener B. A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer (Phila) 1982;49:1721–1733.PubMedCrossRefGoogle Scholar
  33. 33.
    Sears HF, Hopson R, Inouye W, et al. Analysis of staging and management of patients with sarcoma: a ten-year experience. Ann Surg 1980;191:488–493.PubMedCrossRefGoogle Scholar
  34. 34.
    Rydholm A, Berg NO, Gullberg B, et al. Prognosis for soft-tissue sarcoma in the locomotor system: a retrospective population-based follow-up study of 237 patients. APMIS 1984;92:375–386.Google Scholar
  35. 35.
    Heise HW, Myers MH, Russell WO, et al. Recurrence-free survival time for surgically treated soft tissue sarcoma patients: multivariate analysis of five prognostic factors. Cancer (Phila) 1986;57:172–177.PubMedCrossRefGoogle Scholar
  36. 36.
    Rooser B, Attewell R, Berg NO, et al. Survival in soft tissue sarcoma: prognostic variables identified by multivariate analysis. Acta Orthop Scand 1987;58:516–522.PubMedGoogle Scholar
  37. 37.
    Collin CF, Godbold J, Hajdu S, et al. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987;5:601–612.PubMedGoogle Scholar
  38. 38.
    Tsujimoto M, Aozasa K, Ueda T, et al. Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer (Phila) 1988;62:994–998.PubMedCrossRefGoogle Scholar
  39. 39.
    Ueda T, Aozasa K, Tsujimoto M, et al. Multivariate analysis for clinical prognostic factors in 163 patients. Cancer (Phila) 1988;62:1444–1450.PubMedCrossRefGoogle Scholar
  40. 40.
    Rooser B, Attewell R, Berg NO, et al. Prognostication in soft tissue sarcoma: a model with four risk factors. Cancer (Phila) 1988;61:817–823.PubMedCrossRefGoogle Scholar
  41. 41.
    Mandard AM, Petiot JF, Marnay J, et al. Prognostic factors in soft tissue sarcomas: a multivariate analysis of 109 cases. Cancer (Phila) 1989;63:1437–1451.PubMedCrossRefGoogle Scholar
  42. 42.
    Bell RS, O’Sullivan B, Liu FF, et al. The surgical margin in soft-tissue sarcoma. J Bone Joint Surg [Am] 1989;71:370–375.PubMedGoogle Scholar
  43. 43.
    Emrich LJ, Ruka W, Driscoll DL, et al. The effect of local recurrence on survival time in adult high-grade soft tissue sarcomas. J Clin Epidemiol 1989;42:105–110.PubMedCrossRefGoogle Scholar
  44. 44.
    Stotter AT, Ahern RP, Fisher C, et al. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer (Phila) 1990;65:1119–1129.PubMedCrossRefGoogle Scholar
  45. 45.
    Alvegard TA, Berg NO, Baldetorp B, et al. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 1990;8:538–547.PubMedGoogle Scholar
  46. 46.
    Heslin MJ, Cordon-Cardo C, Lewis JJ, et al. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer (Phila) 1998;83:490–497.PubMedCrossRefGoogle Scholar
  47. 47.
    Cance WG, Brennan MF, Dudas ME, et al. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990;323:1457–1462.PubMedGoogle Scholar
  48. 48.
    Karpeh MS, Brennan MF, Cance WG, et al. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995;72:986–991.PubMedGoogle Scholar
  49. 49.
    Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338:153–160.PubMedCrossRefGoogle Scholar
  50. 50.
    Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996;14:1245–1251.PubMedGoogle Scholar
  51. 51.
    de Alava E, Kawai A, Healey JH, et al. EWS-FLII fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol 1998;16:1248–1255.PubMedGoogle Scholar
  52. 52.
    Pisters PWT, Brennan MF. Sarcomas of soft tissue. In: Abeloff M, Armitage J, Lichter A, et al, eds. Clinical Oncology, 1st ed. New York: Churchill Livingstone, 1995:1799–1832.Google Scholar
  53. 53.
    Pisters PWT, Pollock RE. Staging and prognostic factors in soft tissue sarcoma. Semin Radiat Oncol 1999:307–314.Google Scholar
  54. 54.
    Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1990;1:199–206.PubMedGoogle Scholar
  55. 55.
    Drobnjak M, Latres E, Pollack D, et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994;86:549–554.PubMedCrossRefGoogle Scholar
  56. 56.
    Yang P, Hirose T, Hasegawa T, et al. Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. Cancer (Phila) 1995;76:618–625.PubMedCrossRefGoogle Scholar
  57. 57.
    Levine EA, Holzmayer T, Bacus S, et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 1997;15:3249–3257.PubMedGoogle Scholar
  58. 58.
    Rudolph P, Kellner U, Chassevent A, et al. Prognostic relevance of a novel proliferation marker, ki-sll, for soft-tissue sarcoma: a multivariate study. Am J Pathol 1997;150:1997–2007.PubMedGoogle Scholar
  59. 59.
    Williard WC, Collin CF, Casper ES, et al. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 1992;175:389–396.PubMedGoogle Scholar
  60. 60.
    Williard WC, Hajdu SI, Casper ES, et al. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;215:269–275.PubMedGoogle Scholar
  61. 61.
    Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305–315.PubMedCrossRefGoogle Scholar
  62. 62.
    Yang JC, Rosenberg SA. Surgery for adult patients with soft tissue sarcomas. Semin Oncol 1989;16:289–296.PubMedGoogle Scholar
  63. 63.
    Brennan MF, Casper ES, Harrison LB, et al. The role of multi-modality therapy in soft-tissue sarcoma. Ann Surg 1991;214:328–337.PubMedCrossRefGoogle Scholar
  64. 64.
    Bowden L, Booher RJ. The principles and techniques of resection of soft parts for sarcomas. Surgery (St. Louis) 1958;44:963–977.PubMedGoogle Scholar
  65. 65.
    Cantin J, McNeer GP, Chu FC, et al. The problem of local recurrence after treatment of soft tissue sarcoma. Ann Surg 1968;168:47–53.PubMedCrossRefGoogle Scholar
  66. 66.
    Gerner RD, Moore GE, Pickren JW. Soft tissue sarcomas. Ann Surg 1975;181:803–808.PubMedGoogle Scholar
  67. 67.
    Yang JC, Chang AE, Baker AR, et al. A randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197–203.PubMedGoogle Scholar
  68. 68.
    Pisters PWT, Harrison LB, Leung DHY, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859–868.PubMedGoogle Scholar
  69. 69.
    Karakousis CP, Proimakis C, Walsh DL. Primary soft tissue sarcoma of the extremities in adults. Br J Surg 1995;82:1208–1212.PubMedCrossRefGoogle Scholar
  70. 70.
    Karakousis CP. Surgery for soft tissue sarcomas. In: Bland KI, Karakousis CP, Copeland EM, eds. In: Atlas of Surgical Oncology, 1st ed. Philadelphia: Saunders, 1995:283–400.Google Scholar
  71. 71.
    Geer RJ, Woodruff J, Casper ES, et al. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992;127:1285–1289.PubMedGoogle Scholar
  72. 72.
    Rydholm A, Gustafson P, Rooser B, et al. Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. J Clin Oncol 1991;9:1757–1765.PubMedGoogle Scholar
  73. 73.
    Healey B, Corson JM, Demetri GD, et al. Surgery alone may be adequate treatment for select stage IA-IIIA soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol 1995;14:517.Google Scholar
  74. 74.
    Respondek P, Pollack A, Feig BW, et al. Prospective trial of conservative surgery and selective use of radiotherapy for AJCC Tl extremity and trunk soft tissue sarcomas [abstract]. Sarcoma 1997;1:219.Google Scholar
  75. 75.
    Suit HD, Mankin HJ, Schiller AL. Results of treatment of sarcoma of soft tissue by radiation and surgery at Massachusetts General Hospital. Cancer Treat Symp 1985;3:33–47.Google Scholar
  76. 76.
    Barkley HT Jr, Martin RG, Romsdahl MM, et al. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Radiat Oncol Biol Phys 1988;14:693–699.PubMedGoogle Scholar
  77. 77.
    Brant TA, Parsons JT, Marcus RB Jr, et al. Preoperative irradiation for soft tissue sarcomas of the trunk and extremities in adults. Int J Radiat Oncol Biol Phys 1990;19:899–906.PubMedGoogle Scholar
  78. 78.
    Harrison LB, Franzese F, Gaynor JJ, et al. Long term results of a prospective trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys 1993;27:259–265.PubMedGoogle Scholar
  79. 79.
    Lindberg RD, Martin RG, Romsdahl MM, et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer (Phila) 1981;47:2391–2397.PubMedCrossRefGoogle Scholar
  80. 80.
    Karakousis CP, Emrich LJ, Rao U, et al. Feasibililty of limb salvage and survival in soft tissue sarcomas. Cancer (Phila) 1986;57:484–491.PubMedCrossRefGoogle Scholar
  81. 81.
    Suit HD, Mankin HJ, Wood WC, et al. Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol 1988;6:854–862.PubMedGoogle Scholar
  82. 82.
    Lindberg R. Treatment of localized soft tissue sarcomas in adults at MD Anderson Hospital and Tumor Institute (1960–1981). Cancer Treat Symp 1985;3:59–65.Google Scholar
  83. 83.
    Enneking WF, McAuliffe JA. Adjunctive preoperative radiation therapy in treatment of soft tissue sarcomas: a preliminary report. Cancer Treat Symp 1985;3:37–42.Google Scholar
  84. 84.
    Leibel SA, Tranbaugh RF, Wara WM, et al. Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone. Cancer (Phila) 1982;50:1076–1083.PubMedCrossRefGoogle Scholar
  85. 85.
    Suit HD, Mankin HJ, Wood W, et al. Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer (Phila) 1985;55:2659–2667.PubMedCrossRefGoogle Scholar
  86. 86.
    Shiu MH, Hilaris BS, Harrison LB, et al. Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb. Int J Radiat Oncol Biol Phys 1991;21:1485–1492.PubMedGoogle Scholar
  87. 87.
    Willett CG, Suit HD. Limited surgery and external beam irradiation in soft tissue sarcoma. Adv Oncol 1989;5:26–29.Google Scholar
  88. 88.
    Habrand JL, Gerbaulet A, Pejovic MH, et al. Twenty years experience of interstitial iridium brachytherapy in the management of soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1991;20:405–411.PubMedGoogle Scholar
  89. 89.
    Brennan MF, Hilaris B, Shiu MH, et al. Local recurrence in adult soft-tissue sarcoma: a randomized trial of brachytherapy. Arch Surg 1987;122:1289–1293.PubMedGoogle Scholar
  90. 90.
    Pisters PWT, Harrison LB, Woodruff JM, et al. A prospective randomized trial of adjuvant brachytherapy in the management of low grade soft tissue sarcomas of the extremity and superficial trunk. J Clin Oncol 1994;12:1150–1155.PubMedGoogle Scholar
  91. 91.
    Pollack A, Zagars GK, Goswitz MS, et al. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys 1998;42:563–572.PubMedGoogle Scholar
  92. 92.
    Nielsen OS, Cummings B, O’Sullivan B, et al. Preoperative and postoperative irradiation of soft tissue sarcomas: effect of radiation field size. Int J Radiat Oncol Biol Phys 1991;21:1595–1599.PubMedGoogle Scholar
  93. 93.
    Bujko K, Suit HD, Springfield DS, et al. Wound healing after preoperative radiation for sarcoma of soft tissues. Surg Gynecol Obstet 1993;176:124–134.PubMedGoogle Scholar
  94. 94.
    Peat BG, Bell RS, Davis A, et al. Wound-healing complications after soft-tissue sarcoma surgery. Plast Reconstr Surg 1994;93:980–987.PubMedCrossRefGoogle Scholar
  95. 95.
    Janjan NA, Yasko AW, Reece GP, et al. Comparison of charges related to radiotherapy for soft tissue sarcomas treated by preoperative external beam irradiation versus interstitial implantation. Ann Surg Oncol 1994;1:415–422.PubMedCrossRefGoogle Scholar
  96. 96.
    Bui NB, Maree D, Coindre JM, et al. First results of a prospective randomized study of CYVADIC adjuvant chemotherapy in adults with operable high risk soft tissue sarcoma [abstract]. Proc Am Soc Clin Oncol 1989;8:318.Google Scholar
  97. 97.
    Bramwell VHC, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:1137–1149.PubMedGoogle Scholar
  98. 98.
    Glenn J, Sindelar WF, Kinsella T, et al. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery (St. Louis) 1985;97:316–325.PubMedGoogle Scholar
  99. 99.
    Glenn J, Kinsella T, Glatstein E, et al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer (Phila) 1985;55:1206–1214.PubMedCrossRefGoogle Scholar
  100. 100.
    Edmonson JH, Fleming TR, Ivins JC, et al. Randomized study of systemic chemotherapy following complete excision of nonos-seous sarcomas. J Clin Oncol 1984;2:1390–1396.PubMedGoogle Scholar
  101. 101.
    Edmonson JH. Role of adjuvant chemotherapy in the management of patients with soft tissue sarcomas. Cancer Treat Rep 1984;68:1063–1066.PubMedGoogle Scholar
  102. 102.
    Eiber FR, Giuliano AE, Huth JF, et al. A randomized prospective trial using postoperative adjuvant chemotherapy (Adriamycin) in high-grade extremity soft-tissue sarcoma. Am J Clin Oncol 1988;11:39–45.CrossRefGoogle Scholar
  103. 103.
    Alvegard TA, Sigurdsson H, Mouridsen H, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 1989;7:1504–1513.PubMedGoogle Scholar
  104. 104.
    Picci P, Bacci G, Gherlinzoni F, et al. Results of a randomized trial for the treatment of localized soft tissue tumors (STS) of the extremities in adult patients. In: Ryan JR, Baker LO, eds. Recent Concepts in Sarcoma Treatment. Dordrecht: Kluwer, 1988:144–148.Google Scholar
  105. 105.
    Antman K, Amato D, Lerner H. Eastern Cooperative Oncology Group and Dana-Farber Cancer Institute/Massachusetts General Hospital study. In: Jones S, Salmon S, eds. Adjuvant Therapy of Cancer, 4th ed. Orlando: Grune & Stratton, 1984:611–620.Google Scholar
  106. 106.
    Antman K, Anato D, Lerner H, et al. Adjuvant doxorubicin for sarcoma: data from the Eastern Cooperative Oncology Group and Dana-Farber Cancer Institute/Massachusetts General Hospital studies. Cancer Treat Symp 1985;3:109–115.Google Scholar
  107. 107.
    Antman K, Suit H, Amato D, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Oncol 1984;2:601–608.PubMedGoogle Scholar
  108. 108.
    Antman K, Amato D, Pilepich M, et al. A preliminary analysis of a randomized Intergroup (SWOG, ECOG, CALBG, NCOG) trial of adjuvant doxorubicin for soft tissue sarcomas. In: Salmon S, ed. Adjuvant Therapy of Cancer, 5th ed. Orlando: Grune & Stratton, 1987:725–734.Google Scholar
  109. 109.
    Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant Adriamycin uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1240–1245.PubMedGoogle Scholar
  110. 110.
    Rosenberg SA, Tepper J, Glatstein E, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer (Phila) 1983;52:424–434.PubMedCrossRefGoogle Scholar
  111. 111.
    Rosenberg SA. Prospective randomized trials demonstrating the efficacy of adjuvant chemotherapy in adult patients with soft tissue sarcomas. Cancer Treat Rep 1984;68:1067–1078.PubMedGoogle Scholar
  112. 112.
    Chang AE, Kinsella T, Glatstein E, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol 1988;6:1491–1500.PubMedGoogle Scholar
  113. 113.
    Benjamin RS, Terjanian TO, Fenoglio CJ, et al. The importance of combination chemotherapy for adjuvant treatment of high risk patients with soft-tissue sarcomas of the extremities. In: Salmon S, ed. Adjuvant Therapy of Cancer, 5th ed. Orlando: Grune & Stratton, 1987:735–744.Google Scholar
  114. 114.
    Tierney JF. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647–1654.CrossRefGoogle Scholar
  115. 115.
    Frustaci S, Gherlinzoni F, De Paoli A, et al. Preliminary results of an adjuvant randomized trial on high risk extremity soft tissue sarcomas (STS): the interim analysis [abstract]. Proc Am Soc Clin Oncol 1997;16:1785.Google Scholar
  116. 116.
    Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer (Phila) 1983;52:51–60.PubMedCrossRefGoogle Scholar
  117. 117.
    Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–905.PubMedCrossRefGoogle Scholar
  118. 118.
    Singal PK, Iliskovic N, Li T, et al. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997;11:931–936.PubMedGoogle Scholar
  119. 119.
    Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer (Phila) 1991;68:1221–1229.PubMedCrossRefGoogle Scholar
  120. 120.
    Pisters PWT, Patel SR, Varma DGK, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 1997;15:3481–3487.PubMedGoogle Scholar
  121. 121.
    Casper ES, Gaynor JJ, Harrison LB, et al. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer (Phila) 1994;73:1644–1651.PubMedCrossRefGoogle Scholar
  122. 122.
    O’Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer (Phila) 1977;39:1940–1948.PubMedCrossRefGoogle Scholar
  123. 123.
    Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifos-famide in bone and soft tissue sarcomas: results of phase II and pilot studies—dose-response and schedule dependence. J Clin Oncol 1997;15:2378–2384.PubMedGoogle Scholar
  124. 124.
    Gortzak E, Rouesse J, Verwey J, et al. Randomised phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults: protocol 62874. Eur J Cancer 1993;29A(suppl 6):S183.CrossRefGoogle Scholar
  125. 125.
    Eilber FR, Giuliano A, Huth JH, et al. Neoadjuvant chemotherapy, radiation, and limited surgery for high grade soft tissue sarcoma of the extremity. In: Ryan JR, Baker LO, eds. Recent Concepts in Sarcoma Treatment. Dordrecht: Kluwer, 1988:115–122.Google Scholar
  126. 126.
    Eilber FR, Giuliano AE, Huth JF, et al. Postoperative adjuvant chemotherapy (Adriamycin) in high grade extremity soft tissue sarcoma: a randomized prospective trial. In: Salmon SE, ed. Adjuvant Therapy of Cancer, 5th ed. Orlando: Grune & Stratton, 1987:719–723.Google Scholar
  127. 127.
    Eilber FR, Giuliano AE, Huth JF, et al. Intravenous (IV) vs. intraarterial (IA) Adriamycin, 2800r radiation and surgical excision for extremity soft tissue sarcomas: a randomized prospective trial [abstract]. Proc Am Soc Clin Oncol 1990;9:309.Google Scholar
  128. 128.
    Wanebo HJ, Temple WJ, Popp MB, et al. Preoperative regional therapy for extremity sarcoma: a tricenter update. Cancer (Phila) 1995;75:2299–2306.PubMedCrossRefGoogle Scholar
  129. 129.
    Temple WJ, Temple CLF, Arthur K, et al. Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas. Ann Surg Oncol 1997;4:586–590.PubMedCrossRefGoogle Scholar
  130. 130.
    Levine EA, Trippon M, DasGupta TK. Preoperative multimodality treatment for soft tissue sarcomas. Cancer (Phila) 1993;71:3685–3689.PubMedCrossRefGoogle Scholar
  131. 131.
    Spiro IJ, Suit H, Gebhardt MC, et al. Neoadjuvant chemotherapy and radiotherapy for large soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol 1996;15:524.Google Scholar
  132. 132.
    Eggermont AMM, Shraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-g and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653–2665.PubMedGoogle Scholar
  133. 133.
    Begg CB, Cramer LD, Hoskins WJ, et al. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280:1747–1751.PubMedCrossRefGoogle Scholar
  134. 134.
    Birkmeyer JD, Finlayson SR, Tosteson AN, et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery (St. Louis) 1999;125:250–256.PubMedGoogle Scholar
  135. 135.
    Clasby R, Tilling K, Smith MA, et al. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 1997;84:1692–1696.PubMedCrossRefGoogle Scholar
  136. 136.
    Gustafson P, Dreinhofer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center: a comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994;65:47–50.PubMedCrossRefGoogle Scholar
  137. 137.
    Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985;3:353–366.PubMedGoogle Scholar
  138. 138.
    Bevilacqua RG, Rogatko A, Hajdu SI, et al. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. Arch Surg 1991;126:328–334.PubMedGoogle Scholar
  139. 139.
    Farhood Al, Hajdu SI, Shiu MH, et al. Soft tissue sarcomas of the head and neck in adults. Am J Surg 1990;160:365–369.PubMedCrossRefGoogle Scholar
  140. 140.
    Singer S, Antman K, Corson JM, et al. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 1992;127:548–553.PubMedGoogle Scholar
  141. 141.
    Midis GP, Pollock RE, Chen NP, et al. Locally recurrent soft tissue sarcoma of the extremities. Surgery (St. Louis) 1998;123:666–671.PubMedGoogle Scholar
  142. 142.
    Nori D, Schupak K, Shiu MH, et al. Role of brachytherapy in recurrent extremity sarcoma in patients treated with prior surgery and irradiation. Int J Radiat Oncol Biol Phys 1991;20:1229–1233.PubMedGoogle Scholar
  143. 143.
    Pearlstone D, Janjan NA, Feig BW, et al. Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field. Cancer J Sci Am 1999;5:26–33.PubMedGoogle Scholar
  144. 144.
    Catton CN, Davis A, Bell RS, et al. Soft tissue sarcoma of the extremity: limb salvage after failure of combined conservative therapy. Radiother Oncol 1996;41:209–214.PubMedCrossRefGoogle Scholar
  145. 145.
    Barr LC, Stotter AT, A’Hern RP. Influence of local recurrence on survival: a controversy reviewed from the perspective of soft tissue sarcoma. Br J Surg 1991;78:648–650.PubMedCrossRefGoogle Scholar
  146. 146.
    Rooser B, Gustafson P, Rydholm A. Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma? Cancer (Phila) 1990;65:1727–1729.PubMedCrossRefGoogle Scholar
  147. 147.
    Gustafson P, Rooser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer (Phila) 1991;67:2083–2086.PubMedCrossRefGoogle Scholar
  148. 148.
    Lewis JJ, Leung D, Heslin M, et al. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol 1997;15:646–652.PubMedGoogle Scholar
  149. 149.
    Brennan MF. The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. J Am Coll Surg 1996;182:520–529.PubMedGoogle Scholar
  150. 150.
    Billingsley KG, Lewis JJ, Leung DH, et al. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer (Phila) 1999;85:389–395.PubMedCrossRefGoogle Scholar
  151. 151.
    Creagan ET, Fleming TR, Edmonson JH, et al. Pulmonary resection for metastatic nonosteogenic sarcoma. Cancer (Phila) 1979;44:1908–1912.PubMedCrossRefGoogle Scholar
  152. 152.
    Casson AG, Putnam JB, Natarajan G, et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer (Phila) 1992;69:662–668.PubMedCrossRefGoogle Scholar
  153. 153.
    Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft-tissue sarcoma. Ann Surg 1993;218:705–712.PubMedCrossRefGoogle Scholar
  154. 154.
    Huth JF, Holmes EC, Vernon SE, et al. Pulmonary resection for metastatic sarcoma. Am J Surg 1980;140:9–16.PubMedCrossRefGoogle Scholar
  155. 155.
    McCormack PM, Martini N. The changing role of surgery for pulmonary metastases. Ann Thorac Surg 1979;28:139–145.PubMedCrossRefGoogle Scholar
  156. 156.
    Morrow CE, Vassilopoulos PP, Grage TB. Surgical resection for metastatic neoplasms of the lung: experience at the University of Minnesota Hospitals. Cancer (Phila) 1980;45:2981–2985.PubMedCrossRefGoogle Scholar
  157. 157.
    Mountain CF, McMurtney Mf, Hermes KE. Surgery for pulmonary metastasis: a 20-year experience. Ann Thorac Surg 1984;38:323–330.PubMedCrossRefGoogle Scholar
  158. 158.
    Pastorino U, Valente M, Gasparini M, et al. Lung resection for metastatic sarcomas: total survival from primary treatment. J Surg Oncol 1989;4:275–280.CrossRefGoogle Scholar
  159. 159.
    Rizzoni WE, Pass HI, Wesley MN, et al. Resection of recurrent pulmonary metastases in patients with soft-tissue sarcomas. Arch Surg 1986;121:1248–1252.PubMedCrossRefGoogle Scholar
  160. 160.
    van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer (Phila) 1996;77:675–682.PubMedCrossRefGoogle Scholar
  161. 161.
    Putnam JB Jr, Roth JA, Wesley MN, et al. Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1984;87:260–268.PubMedGoogle Scholar
  162. 162.
    Jablons D, Steinberg SM, Roth J, et al. Metastasectomy for soft tissue sarcoma: further evidence for efficacy and prognostic indicators. J Thorac Cardiovasc Surg 1989;97:695–705.PubMedGoogle Scholar
  163. 163.
    Roth JA, Putnam JB Jr, Wesley MN, et al. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer (Phila) 1985;55:1361–1366.PubMedCrossRefGoogle Scholar
  164. 164.
    Pogrebniak HW, Roth JA, Steinberg SM, et al. Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma. Ann Thorac Surg 1991;52:197–203.PubMedCrossRefGoogle Scholar
  165. 165.
    Casson AG, Putnam JB, Natarajan G, et al. Efficacy of pulmonary metastasectomy for recurrent soft tissue sarcoma. J Surg Oncol 1991;47:1–4.PubMedCrossRefGoogle Scholar
  166. 166.
    Takita H, Edgerton F, Karakousis C, et al. Surgical management of metastases to the lung. Surg Gynecol Obstet 1981;152:191–194.PubMedGoogle Scholar
  167. 167.
    Putnam JB Jr, Roth JA, Wesley MN, et al. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg 1983;36:516–523.PubMedCrossRefGoogle Scholar
  168. 168.
    Regnard JF, Cerrina J, Silbert D. Curative surgical treatment of pulmonary metastases. In: Proceedings of 3rd European Conference on Clinical Oncology, Stockholm, Sweden, 1985:58.Google Scholar
  169. 169.
    Ramming KP. Surgery for pulmonary metastases. Surg Clin N Am 1980;60:815–824.PubMedGoogle Scholar
  170. 170.
    Joseph WL, Morton DL, Adkins PC. Prognostic significance of tumor doubling time in evaluating operability in pulmonary metastatic disease. J Thorac Cardiovasc Surg 1971;61:23–32.PubMedGoogle Scholar
  171. 171.
    Verazin GT, Warneke JA, Driscoll DL, et al. Resection of lung metastases from soft-tissue sarcomas: a multivariate analysis. Arch Surg 1992;127:1407–1411.PubMedGoogle Scholar
  172. 172.
    McCormack P. Surgical resection of pulmonary metastases. Semin Surg Oncol 1990;6:297–302.PubMedCrossRefGoogle Scholar
  173. 173.
    Jacobs EM. Combination chemotherapy of metastatic testicular germinal cell tumors and soft part sarcomas. Cancer (Phila) 1970;25:324–332.PubMedCrossRefGoogle Scholar
  174. 174.
    Greenhall MJ, Magill GB, DeCosse JJ, et al. Chemotherapy for soft tissue sarcoma. Surg Gynecol Obstet 1986;162:193–198.Google Scholar
  175. 175.
    Schoenfeld DA, Rosenbaum C, Horton J, et al. A comparison of Adriamycin versus vincristine and Adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer (Phila) 1982;50:2757–2762.PubMedCrossRefGoogle Scholar
  176. 176.
    O’Bryan RM, Luce JK, Talley R, et al. Phase II evaluation of Adriamycin in human neoplasia. Cancer (Phila) 1973;32:1–8.PubMedCrossRefGoogle Scholar
  177. 177.
    Cruz AB Jr, Thames EA Jr, Aust JB, et al. Combination chemotherapy for soft-tissue sarcomas: a phase III study. J Surg Oncol 1979;11:313–323.PubMedCrossRefGoogle Scholar
  178. 178.
    Creagan ET, Hahn RG, Ahmann DL, et al. A clinical trial of Adriamycin (NSC 123127) in advanced sarcomas. Oncology 1977;34:90–91.PubMedGoogle Scholar
  179. 179.
    Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840–850.PubMedGoogle Scholar
  180. 180.
    Gottlieb JA, Baker LH, O’Bryan RM, et al. Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcoma. Cancer Chemother Rep 1975;6 (part 3):271–282.Google Scholar
  181. 181.
    Baker LH, Frank JA, Fine G, et al. Combination chemotherapy using Adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial (a phase in, Southwest Oncology Group Study (7613)). J Clin Oncol 1987;5:851–861.PubMedGoogle Scholar
  182. 182.
    Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase in trial of the Gynecologic Oncology Group). Cancer (Phila) 1985;55:1648–1653.PubMedCrossRefGoogle Scholar
  183. 183.
    Borden EC, Amato DA, Edmonson JH, et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer (Phila) 1990;66:862–867.PubMedCrossRefGoogle Scholar
  184. 184.
    Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 1976;60:199–203.PubMedGoogle Scholar
  185. 185.
    Luce JK, Thurman WG, Isaacs BL, et al. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). Cancer Chemother Rep 1970;54:119–124.PubMedGoogle Scholar
  186. 186.
    Omura GA, Major FJ, Blessing JA, et al. A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer (Phila) 1983;52:626–632.PubMedCrossRefGoogle Scholar
  187. 187.
    Zalupski M, Metch B, Balcerzak SP, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83:926–932.PubMedCrossRefGoogle Scholar
  188. 188.
    Selawry OS, Holland JF, Wolman IJ. Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep 1968;52:497–500.PubMedGoogle Scholar
  189. 189.
    Korbitz BC, Davis HL Jr, Ramirez G, et al. Low doses of vincristine (NSC-67574) for malignant disease. Cancer Chemother Rep 1969;53:249–253.PubMedGoogle Scholar
  190. 190.
    Ravaud A, Nguyen BB, Coindre JM, et al. Adjuvant chemotherapy with CyVADIC in high-grade soft tissue sarcoma: a randomized prospective trial. In: Salmon S, ed. Adjuvant Therapy of Cancer, 6th ed. Philadelphia: Saunders, 1990:556–566.Google Scholar
  191. 191.
    Bramwell VHC, Rouesse J, Steward W, et al. European experience of adjuvant chemotherapy for soft tissue sarcoma: interim report of a randomized trial of CYVADIC versus control. In: Ryan JR, Baker LO, eds. Recent Concepts in Sarcoma Treatment. Dordrecht: Kluwer, 1988:157–159.Google Scholar
  192. 192.
    Yap BS, Baker LH, Sinkovics JG, et al. Cyclophosphamide, vincristine, Adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 1980;64:93–98.PubMedGoogle Scholar
  193. 193.
    Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537–1545.PubMedGoogle Scholar
  194. 194.
    Antman KH, Ryan L, Elias AD, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126–131.PubMedGoogle Scholar
  195. 195.
    Antman KH, Montella D, Rosenbaum C, et al. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 1985;69:499–504.PubMedGoogle Scholar
  196. 196.
    Stuart-Harris R, Harper PG, Kaye SB, et al. High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 1983;10(suppl A).163–164.PubMedCrossRefGoogle Scholar
  197. 197.
    Bramwell VHC, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987;23:311–321.PubMedCrossRefGoogle Scholar
  198. 198.
    Morgan LR, Posey LE, Rainey J, et al. Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 1981;65:693–695.PubMedGoogle Scholar
  199. 199.
    Brock N, Pohl J. The development of mesna for regional detoxification. Cancer Treat Rev 1983;10(suppl A):33–43.PubMedCrossRefGoogle Scholar
  200. 200.
    Wiltshaw E, Westbury G, Harmer C, et al. Ifosfamide plus mesna with and without Adriamycin in soft tissue sarcoma. Cancer Chemother Pharmacol 1986;18(suppl 2):S10–S12.PubMedCrossRefGoogle Scholar
  201. 201.
    Schutte J, Mouridsen HT, Stewart W, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma: the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1990;26:558–561.PubMedCrossRefGoogle Scholar
  202. 202.
    Elias AD, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208–1216.PubMedGoogle Scholar
  203. 203.
    Elias AD, Ryan L, Aisner J, et al. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 1990;17:41–49.PubMedGoogle Scholar
  204. 204.
    Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269–1275.PubMedGoogle Scholar
  205. 205.
    Antman K, Crowley J, Balcerzak SP, et al. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276–1285.PubMedGoogle Scholar
  206. 206.
    Jaques DP, Coit DG, Hajdu SI, et al. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg 1990;212:51–59.PubMedCrossRefGoogle Scholar
  207. 207.
    Alvarenga JC, Ball AB, Fisher C, et al. Limitations of surgery in the treatment of retroperitoneal sarcoma. Br J Surg 1991;78:912–916.PubMedCrossRefGoogle Scholar
  208. 208.
    Neifeld JP, Walsh JW, Lawrence W Jr. Computed tomography in the management of soft tissue tumors. Surg Gynecol Obstet 1982;155:535–540.PubMedGoogle Scholar
  209. 209.
    Sundaram M, McLeod RA. MR imaging of tumor and tumor like lesions of bone and soft tissue. AJR Am J Roentgenol 1990;155:817–824.PubMedGoogle Scholar
  210. 210.
    Manaser BJ, Ensign MF. Imaging of musculoskeletal tumors. Semin Oncol 1991;18:140–149.Google Scholar
  211. 211.
    Karakousis CP, Velez AF, Emrich LJ. Management of retroperitoneal sarcomas and patient survival. Am J Surg 1985;150:376–380.PubMedCrossRefGoogle Scholar
  212. 212.
    Dalton RR, Donohue JH, Mucha P Jr, et al. Management of retroperitoneal sarcomas. Surgery (St. Louis) 1989;106:725–733.PubMedGoogle Scholar
  213. 213.
    Storm FK, Mahvi DM. Diagnosis and management of retroperitoneal soft-tissue sarcoma. Ann Surg 1991;214:2–10.PubMedCrossRefGoogle Scholar
  214. 214.
    Karakousis CP, Velez AF, Gerstenbluth R, et al. Resectability and survival in retroperitoneal sarcomas. Ann Surg Oncol 1996;3:150–158.PubMedCrossRefGoogle Scholar
  215. 215.
    Kilkenny JW III, Bland KI, Copeland EM III. Retroperitoneal sarcoma: the University of Florida experience. J Am Coll Surg 1996;182:329–339.PubMedGoogle Scholar
  216. 216.
    Karakousis CP, Kontzoglou K, Driscoll DL. Resectability of retroperitoneal sarcomas: a matter of surgical technique? Eur J Surg Oncol 1995;21:617–622.PubMedCrossRefGoogle Scholar
  217. 217.
    Karakousis CP, Gerstenbluth R, Kontzoglou K, et al. Retroperitoneal sarcomas and their management. Arch Surg 1995;130:1104–1109.PubMedGoogle Scholar
  218. 218.
    Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355–365.PubMedCrossRefGoogle Scholar
  219. 219.
    McGrath PC, Neifeld JP, Lawrence W Jr, et al. Improved survival following complete excision of retroperitoneal sarcomas. Ann Surg 1984;200:200–204.PubMedCrossRefGoogle Scholar
  220. 220.
    Heslin MJ, Lewis JJ, Nadler E, et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol 1997;15:2832–2839.PubMedGoogle Scholar
  221. 221.
    Catton CN, O’Sullivan B, Kotwall C, et al. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1994;29:1005–1010.PubMedGoogle Scholar
  222. 222.
    Bose B. Primary malignant retroperitoneal tumours: analysis of 30 cases. Can J Surg 1979;22:215–220.PubMedGoogle Scholar
  223. 223.
    Cody HSI, Turnbull AD, Fortner JG, et al. The continuing challenge of retroperitoneal sarcomas. Cancer (Phila) 1981;47:2147–2152.PubMedCrossRefGoogle Scholar
  224. 224.
    Harrison LB, Gutierrez E, Fischer JJ. Retroperitoneal sarcomas: the Yale experience and a review of the literature. J Surg Oncol 1986;32:159–164.PubMedCrossRefGoogle Scholar
  225. 225.
    Wist E, Solheim OP, Jacobsen AB, et al. Primary retroperitoneal sarcomas: a review of 36 cases. Acta Radiol Oncol 1985;24:305–310.PubMedCrossRefGoogle Scholar
  226. 226.
    Tepper JE, Suit HD, Wood WC, et al. Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1984;10:825–830.PubMedGoogle Scholar
  227. 227.
    Willett CG, Suit HD, Tepper JE, et al. Intraoperative electron beam radiation therapy for retroperitoneal soft tissue sarcoma. Cancer (Phila) 1991;68:278–283.PubMedCrossRefGoogle Scholar
  228. 228.
    Kinsella TJ, Sindelar WF, Lack E, et al. Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. J Clin Oncol 1988;6:18–25.PubMedGoogle Scholar
  229. 229.
    Sindelar WF, Kinsella TJ, Chen PW, et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg 1993;128:402–410.PubMedGoogle Scholar
  230. 230.
    Storm FK, Eilber FR, Mirra J, et al. Retroperitoneal sarcomas: a reappraisal of treatment. J Surg Oncol 1981;17:1–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Peter W. T. Pisters
    • 1
  1. 1.Department of Surgical OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations